Abstract:Key Teaching Points•Since genetic testing for long QT syndrome exerts a substantial diagnostic, prognostic, and therapeutic impact for the index cases and their affected family members, it is of critical importance to identify the exact disease-causing mutation and to properly rule out benign variants.•The article contains a fundamentally important message and dispels a commonly held perception, namely, that identification of a rare variant does not automatically equate to a disease diagnosis.•Even KCNQ1 mutations within areas of high probability of pathogenicity (ie, transmembrane spanning or pore-forming regions) or indicated by a genetic test company as “deleterious” should be interpreted with caution, especially if the variant-positive individuals have insufficient clinical evidence for a diagnosis of long QT syndrome in the first place.•It is important that physicians analyze the veracity and concordance of the evidence underpinning both the alleged genotype and the alleged phenotype. If discordance exists, one must be critical of any genetic test company's interpretation and tread carefully with the use of the genotypic data in their clinical decision making.•Genetic testing continues to be perceived as the ultimate diagnostic arbiter, yet the perils of testing in a poorly phenotyped family can be significant as illustrated in this case, with major implications for the family in terms of medical care, potential restrictions, insurance, and the psychological burden such a diagnosis brings. •Since genetic testing for long QT syndrome exerts a substantial diagnostic, prognostic, and therapeutic impact for the index cases and their affected family members, it is of critical importance to identify the exact disease-causing mutation and to properly rule out benign variants.•The article contains a fundamentally important message and dispels a commonly held perception, namely, that identification of a rare variant does not automatically equate to a disease diagnosis.•Even KCNQ1 mutations within areas of high probability of pathogenicity (ie, transmembrane spanning or pore-forming regions) or indicated by a genetic test company as “deleterious” should be interpreted with caution, especially if the variant-positive individuals have insufficient clinical evidence for a diagnosis of long QT syndrome in the first place.•It is important that physicians analyze the veracity and concordance of the evidence underpinning both the alleged genotype and the alleged phenotype. If discordance exists, one must be critical of any genetic test company's interpretation and tread carefully with the use of the genotypic data in their clinical decision making.•Genetic testing continues to be perceived as the ultimate diagnostic arbiter, yet the perils of testing in a poorly phenotyped family can be significant as illustrated in this case, with major implications for the family in terms of medical care, potential restrictions, insurance, and the psychological burden such a diagnosis brings.

Abstract 16901: Utilizing in Silico Pathogenicity Prediction Tools and Heterologous Expression Patch Clamp Studies to Identify Bona Fide Pathogenic KCNH2 Variants among Publically Available Exomes Derived from Subjects Without Evidence for Either Type 2 Long QT Syndrome or Type 1 Short QT Syndrome

Utilization of the Genome Aggregation Database, in Silico Tools, and Heterologous Expression Patch Clamp Studies to Identify and Demote Previously Published Type 2 Long QT Syndrome-Causative Variants from Pathogenic to Likely Benign.

Using the genome aggregation database, computational pathogenicity prediction tools, and patch clamp heterologous expression studies to demote previously published long QT syndrome type 1 mutations from pathogenic to benign.

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Identification of a KCNE2 Gain-of-Function Mutation in Patients with Familial Atrial Fibrillation

Clinical interpretation of KCNH2 variants using a robust PS3/BS3 functional patch-clamp assay

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Assays of Variant Effect and Automated Patch Clamping Improve KCNH2-LQTS Variant Classification and Cardiac Event Risk Stratification

Α-1-syntrophin Mutation and the Long-QT Syndrome

Prognostic Value of Multiplexed Assays of Variant Effect and Automated Patch-clamping for KCNH2-LQTS Risk Stratification

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Clinical and functional reappraisal of alleged type 5 long QT syndrome: Causative genetic variants in the KCNE1-encoded minK β-subunit.

Identification and characterization of two novel KCNH2 mutations contributing to long QT syndrome

Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome

Mutation Analysis of Potassium Channel Genes KCNQ1 and KCNH2 in Patients with Long QT Syndrome

Prognostic Implications of Mutation-Specific QTc Standard Deviation in Congenital Long QT Syndrome.

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events

Even Pore-Localizing Missense Variants at Highly Conserved Sites in KCNQ1-encoded Kv7.1 Channels May Have Wild-Type Function and Not Cause Type 1 Long QT Syndrome: Do Not Rely Solely on the Genetic Test Company's Interpretation.

A Phenotype-Enhanced Variant Classification Framework to Decrease the Burden of Missense Variants of Uncertain Significance in Type 1 Long QT Syndrome